Donating used CARs

Blood. 2013 Dec 12;122(25):4007-9. doi: 10.1182/blood-2013-10-528984.

Abstract

In this issue of Blood, Kochenderfer et al show that engineered CD19–chimeric antigen receptor (CAR) and donor-derived allogeneic T cells can safely treat CD19-positive B-cell malignancies, which have relapsed after allogeneic stem cell transplantation.

Publication types

  • Comment

MeSH terms

  • Antigens, CD19*
  • Female
  • Humans
  • Lymphocyte Transfusion*
  • Lymphoma, B-Cell / therapy*
  • Male
  • Receptors, Antigen, T-Cell / biosynthesis*
  • Stem Cell Transplantation*
  • T-Lymphocytes / metabolism*
  • T-Lymphocytes / transplantation*

Substances

  • Antigens, CD19
  • Receptors, Antigen, T-Cell